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Background
AIDS is mainly a sexually transmitted disease and accord-
ingly, mucosal tissues are the primary sites of natural HIV-
1 transmission. Mucosal IgA antibody specific for HIV-1
envelope gp41-subunit is one correlate of protection in
individuals who are highly sexually exposed to HIV-1 but
remain persistently IgG seronegative (HEPS). Under-
standing these peculiar IgAs at the gene and functional
level is only possible with monoclonal IgAs.
Methods
We have constructed a mucosal Fab IgA library from HEPS
and have characterized a series of HIV-1 IgAs specific for
gp41 at the functional level against HIV-1 transcytosis and
CD4+ cell infection and analyzed the IgA fab genes
Results
These IgA are transcytosis-blocking and infection-neutral-
izing in the nM range using primary B clade viruses. Char-
acterization of their IgA genes shows that Fab specific for
gp41-membrane proximal region harbors a long CDRH3
similar to the two broadly neutralizing IgG monoclonal
antibodies, 2F5 and 4E10. Furthermore, the selected Fab
IgA exhibits extensive somatic mutations that cluster in
the CDR regions, indicating that affinity maturation due
to an antigen driven process had occurred in HEPS, pre-
sumably upon multiple exposures to HIV.
Conclusion
The present analysis of HEPS monoclonal IgA gives a
unique opportunity to correlate antibody function (resist-
ance to a pathogen in vivo) to antibody gene. Such neutral-
izing monoclonal IgA could be used in microbicide
formulation.
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